Entera Bio (NASDAQ:ENTX) Price Target Lowered to $9.00 at HC Wainwright

Entera Bio (NASDAQ:ENTX) had its target price decreased by HC Wainwright from $10.00 to $9.00 in a research note published on Monday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Entera Bio in a research note on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Entera Bio currently has an average rating of “Hold” and a consensus price target of $9.00.

Entera Bio Trading Up 2.7%

Shares of NASDAQ:ENTX opened at $1.15 on Monday. The stock’s 50-day moving average price is $1.26 and its 200-day moving average price is $1.78. Entera Bio has a 12-month low of $0.91 and a 12-month high of $3.22. The stock has a market capitalization of $53.61 million, a P/E ratio of -4.42 and a beta of 1.54.

Entera Bio (NASDAQ:ENTX) last announced its quarterly earnings data on Friday, March 27th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. As a group, research analysts predict that Entera Bio will post -0.68 EPS for the current year.

Insider Activity

In related news, Director Geno J. Germano acquired 20,000 shares of Entera Bio stock in a transaction dated Monday, March 9th. The shares were purchased at an average cost of $1.30 per share, with a total value of $26,000.00. Following the completion of the purchase, the director owned 40,000 shares of the company’s stock, valued at $52,000. This represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders bought 58,000 shares of company stock worth $72,620 over the last quarter. 10.38% of the stock is currently owned by company insiders.

Institutional Trading of Entera Bio

Institutional investors have recently modified their holdings of the company. Superstring Capital Management LP purchased a new stake in shares of Entera Bio during the fourth quarter worth about $33,000. Citadel Advisors LLC boosted its holdings in shares of Entera Bio by 243.0% during the third quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock worth $77,000 after purchasing an additional 28,322 shares during the period. HighTower Advisors LLC boosted its holdings in shares of Entera Bio by 137.8% during the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after purchasing an additional 25,000 shares during the period. Jane Street Group LLC boosted its holdings in shares of Entera Bio by 142.6% during the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after purchasing an additional 43,536 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in shares of Entera Bio by 22.2% during the fourth quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after purchasing an additional 19,601 shares during the period. 14.11% of the stock is currently owned by hedge funds and other institutional investors.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.